Extended Data Table 1 |.
Binding a | cAMPb | β-arrestin2b | |||||
---|---|---|---|---|---|---|---|
|
|||||||
Ligands | Ki ± SEM (nM) | EC50 (nM) | pEC50 ± SEM | Emax ± SEM (%) | EC50 (nM) | pEC50 ± SEM | Emax ± SEM (%) |
C3 amino | > 1000 | 12300 | 4.9 ± 0.2 | 142 ± 20 | n.d. | n.d. | 8.2 ± 1.1 |
C3 guano | 77 ± 3.0 | 164 | 6.8 ± 0.1 | 107 ± 2.3 | n.d. | n.d. | 6.9 ± 2.4 |
C5 amino | 1179 ± 13 | 469 | 6.3 ± 0.2 | 90 ± 5.9 | n.d. | n.d. | n.d. |
C5 guano | 4.6 ± 0.7 | 0.8 | 9.1 ± 0.1 | 104 ± 3.1 | 4710 | 5.3 ± 0.1 | 54 ± 3.2 |
C6 amino | 1033 ± 15 | 844 | 6.1 ± 0.1 | 126 ± 4.7 | n.d. | n.d. | 20 ± 2.3 |
C6 guano | 4.1 ± 0.3 | 4.7 | 8.3 ± 0.1 | 137 ± 2.1 | n.d. | n.d. | 19 ± 1.4 |
C7 amino | 369 ± 7.0 | 436 | 6.4 ± 0.1 | 109 ± 3.9 | n.d. | n.d. | n.d. |
C7 guano | 41 ± 8.0 | 62 | 7.2 ± 0.1 | 109 ± 2.4 | n.d. | n.d. | 13 ± 1.4 |
C9 amino | 281 ± 2.2 | 360 | 6.4 ± 0.1 | 106 ± 4.6 | 66720 | 4.2 ± 0.2 | 56 ± 9.4 |
C9 guano | 58 ± 8.0 | 21.3 | 7.7 ± 0.1 | 128 ± 3.2 | 792 | 5.1 ± 0.1 | 120 ± 6.6 |
C11amino | 589 ± 13 | 293.2 | 6.5 ± 0.1 | 105 ± 3.6 | n.d. | n.d. | n.d |
C11 guano | 165 ± 4 | 1020 | 6.0 ± 0.1 | 118 ± 5.2 | n.d. | n.d. | n.d. |
Fentanyl | 9.1 ± 3.1 | 0.90 | 9.0 ± 0.1 | 86 ± 1.8 | 66.2 | 7.2 ± 0.1 | 119 ± 2.7 |
DAMGO | n.d. | 0.40 | 9.4 ± 0.1 | 99 ± 4 | 723 | 6.1 ± 0.1 | 100 ± 2.8 |
Ki binding competition studies were performed with the indicated compound against 125I-IBNtxA (0.1 nM) in membranes from CHO cells stably expressing the μOR cloned mouse opioid receptor. Results are presented as Ki ± SEM (nM) from three independent experiments performed in triplicate.
Potency and efficacy data were obtained using agonist induced inhibition measured by cyclic AMP (cAMP) and Tango assay for β-arrestin 2 recruitment, respectively, from three independent experiments performed in triplicate. Efficacy is represented as EC50 (nM) and percent maximal stimulation (Emax) relative to standard agonist DAMGO. “n.d.” Denotes not determined. Efficacy<20%.